Literature DB >> 14977293

Managing the metabolic and morphologic complications of HIV.

M Keith Rawlings1, Guillermo Santos.   

Abstract

Mesh：

Year:  2004        PMID： 14977293      PMCID： PMC2640587     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN： 0027-9684            Impact factor:   1.798


× No keyword cloud information.
  12 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 2.  Metabolic disturbances and wasting in the acquired immunodeficiency syndrome.

Authors:  C Grunfeld; K R Feingold
Journal:  N Engl J Med       Date:  1992-07-30       Impact factor: 91.245

3.  Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection.

Authors:  S R Penzak; S K Chuck; G V Stajich
Journal:  Pharmacotherapy       Date:  2000-09       Impact factor: 4.705

Review 4.  Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

Authors:  Morris Schambelan; Constance A Benson; Andrew Carr; Judith S Currier; Michael P Dubé; John G Gerber; Steven K Grinspoon; Carl Grunfeld; Donald P Kotler; Kathleen Mulligan; William G Powderly; Michael S Saag
Journal:  J Acquir Immune Defic Syndr       Date:  2002-11-01       Impact factor: 3.731

5.  Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.

Authors:  C Hadigan; J B Meigs; C Corcoran; P Rietschel; S Piecuch; N Basgoz; B Davis; P Sax; T Stanley; P W Wilson; R B D'Agostino; S Grinspoon
Journal:  Clin Infect Dis       Date:  2000-12-15       Impact factor: 9.079

6.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.

Authors:  Samuel A Bozzette; Christopher F Ake; Henry K Tam; Sophia W Chang; Thomas A Louis
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

7.  Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation.

Authors:  R Zangerle; M Sarcletti; H Gallati; G Reibnegger; H Wachter; D Fuchs
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-11

8.  Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection.

Authors:  Gail Shor-Posner; Abdul Basit; Ying Lu; Claudio Cabrejos; Jeani Chang; Maryann Fletcher; Emilio Mantero-Atienza; Marianna K Baum
Journal:  Am J Med       Date:  1993-05       Impact factor: 4.965

9.  Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.

Authors:  R Walli; O Herfort; G M Michl; T Demant; H Jäger; C Dieterle; J R Bogner; R Landgraf; F D Goebel
Journal:  AIDS       Date:  1998-10-22       Impact factor: 4.177

10.  The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B.

Authors:  K R Feingold; R M Krauss; M Pang; W Doerrler; P Jensen; C Grunfeld
Journal:  J Clin Endocrinol Metab       Date:  1993-06       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.